Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
15 déc. 2022 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
28 sept. 2022 07h12 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
22 août 2022 07h12 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
06 juil. 2022 07h12 HE
|
Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
21 juin 2022 07h12 HE
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
08 juin 2022 07h12 HE
|
Resverlogix Corp
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
17 mars 2022 07h15 HE
|
Resverlogix Corp
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
22 févr. 2022 07h15 HE
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
ASCEND Unveils Visionary Agenda, Inspiring Speakers, and Community Spirit
30 sept. 2021 13h15 HE
|
AIAA
RESTON, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- ASCEND, the interdisciplinary community focused on building humanity’s off-world future faster, today unveiled its six-day agenda packed with hundreds...
“Fast Forward,” ASCEND’s New On-Demand Interview Series, Envisions Our Off-World Future
07 sept. 2021 12h15 HE
|
AIAA
RESTON, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ASCEND, the only community on the planet dedicated to building humanity’s off-world future faster, today premiered “Fast Forward” – an original...